N4 Pharma PLC. Stock Analysis N4P.L

N4 Pharma Plc is a pharmaceutical company, which engages in the reformulation of existing drugs and vaccines. The company is headquartered in Derby, Derbyshire and currently employs 4 full-time employees. The company went IPO on 2005-06-07. The firm is engaged in developing Nuvec, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. The firm is building out its preclinical dataset and working towards first-in-human clinical data to support licensing deals for its Nuvec platform with gene therapy partners. Its lead program, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept program showcasing all the benefits of the Nuvec platform. ECP105 is a siRNA therapy intended for injection into the ocular cavity and contains a proprietary siRNA sequence to silence the fibrotic gene responsible for fibrosis (MRTF-B), or scarring, which occurs post-surgery. LipTide is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells.